Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1998 Mar;227(3):390–397. doi: 10.1097/00000658-199803000-00011

Effect of glucagon on protein synthesis in human rectal cancer in situ.

W H Hartl 1, H Demmelmair 1, K W Jauch 1, B Koletzko 1, F W Schildberg 1
PMCID: PMC1191277  PMID: 9527062

Abstract

OBJECTIVE: The purpose of this study was to determine the effect of glucagon or placebo on the rate of tumor fractional protein synthesis in situ in patients with localized rectal cancer who were not malnourished, demonstrated normal glucagon concentrations, and could therefore be used as a model to study the glucagon effect. SUMMARY BACKGROUND DATA: Cancer cachexia is associated with an increased concentration of counterregulatory hormones, including glucagon. This altered hormonal milieu may not only contribute to malnutrition, but also promote tumor growth, because previous experimental work suggests that glucagon can cause human colorectal tumor cells to proliferate. Corresponding mechanisms in vivo have, thus far, not been investigated. METHODS: Advanced mass spectrometry techniques (capillary gas chromatography [GC]/combustion isotope ratio mass spectrometry [IRMS]) were used to determine directly the incorporation rate of 1-[13C]-leucine into tissue protein. Because GC/IRMS requires only a small sample volume, three consecutive endoscopic biopsies could be obtained from the same tumor to determine isotopic enrichments at baseline, after a 4-hour glucagon infusion (3 ng/kg/min), or after placebo. RESULTS: In patients with localized rectal cancer, glucagon caused the tumor fractional protein synthetic rate to double (2.25+/-0.49 %/hr, p < 0.05 vs. 1.16+/-0.30 basal). In contrast, tumor protein synthesis declined over time in controls (placebo) (0.67+/-0.09 %/hr, p < 0.05 vs. 1.11+/-0.16 basal). CONCLUSIONS: Tumor protein synthesis and growth can be stimulated by glucagon in situ. Therefore, elevated glucagon concentrations in cachectic cancer patients should be considered detrimental and attempts made to prevent this specific response of the body to the malignant disease.

Full text

PDF
390

Images in this article

394Figure 1.
on p.394

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett D. L., Charland S. L., Torosian M. H. Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia. Surgery. 1995 Jul;118(1):87–97. doi: 10.1016/s0039-6060(05)80014-5. [DOI] [PubMed] [Google Scholar]
  2. Braatvedt G. D., Stanners A., Newrick P. G., Halliwell M., Corrall R. J. Evidence against a putative role for glucagon as a physiological splanchnic vasodilator in man. Clin Sci (Lond) 1993 Feb;84(2):193–199. doi: 10.1042/cs0840193. [DOI] [PubMed] [Google Scholar]
  3. Burt M. E., Aoki T. T., Gorschboth C. M., Brennan M. F. Peripheral tissue metabolism in cancer-bearing man. Ann Surg. 1983 Dec;198(6):685–691. doi: 10.1097/00000658-198312000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buzby G. P., Mullen J. L., Stein T. P., Miller E. E., Hobbs C. L., Rosato E. F. Host-tumor interaction and nutrient supply. Cancer. 1980 Jun 15;45(12):2940–2948. doi: 10.1002/1097-0142(19800615)45:12<2940::aid-cncr2820451208>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  5. Carraro F., Stuart C. A., Hartl W. H., Rosenblatt J., Wolfe R. R. Effect of exercise and recovery on muscle protein synthesis in human subjects. Am J Physiol. 1990 Oct;259(4 Pt 1):E470–E476. doi: 10.1152/ajpendo.1990.259.4.E470. [DOI] [PubMed] [Google Scholar]
  6. Darling G., Goldstein D. S., Stull R., Gorschboth C. M., Norton J. A. Tumor necrosis factor: immune endocrine interaction. Surgery. 1989 Dec;106(6):1155–1160. [PubMed] [Google Scholar]
  7. Dembrow V. D. The role of the surgical oncologist in the community hospital. Arch Surg. 1986 Nov;121(11):1231–1232. doi: 10.1001/archsurg.121.11.1231. [DOI] [PubMed] [Google Scholar]
  8. Douglas R. G., Shaw J. H. Metabolic effects of cancer. Br J Surg. 1990 Mar;77(3):246–254. doi: 10.1002/bjs.1800770305. [DOI] [PubMed] [Google Scholar]
  9. Drott C., Svaninger G., Lundholm K. Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients. Ann Surg. 1988 Nov;208(5):645–650. doi: 10.1097/00000658-198811000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fatemi S. H., Cullan G. E., Sharp J. G. Evaluation of the effects of pentagastrin, gastrin and pancreatic glucagon on cell proliferation in the rat gastrointestinal tract. Cell Tissue Kinet. 1984 Mar;17(2):119–133. doi: 10.1111/j.1365-2184.1984.tb00574.x. [DOI] [PubMed] [Google Scholar]
  11. Feruglio F. S., Greco F., Cesano L., Colongo P. G., Sardi G., Chiandussi L. The effects of glucagon on systemic and hepatosplanchnic haemodynamics and on net peripheral and hepatosplanchnic balance of glucose, lactic and pyruvic acids in normal subjects and cirrhotics. Clin Sci. 1966 Feb;30(1):43–50. [PubMed] [Google Scholar]
  12. Finney K. J., Appleton D. R., Ince P., Moorghen M., Elliott K., Watson A. J. Effects of gastrointestinal peptides on azoxymethane-treated colonic mucosa in vitro. Carcinogenesis. 1991 Nov;12(11):2017–2022. doi: 10.1093/carcin/12.11.2017. [DOI] [PubMed] [Google Scholar]
  13. Frank J. L., Lawrence W., Jr, Banks W. L., Jr, McKinnon J. G., Chan W. M., Collins J. M. Modulation of cell cycle kinetics in human cancer with total parenteral nutrition. Cancer. 1992 Apr 1;69(7):1858–1864. doi: 10.1002/1097-0142(19920401)69:7<1858::aid-cncr2820690731>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  14. Friess H., Böhm J., Müller M. W., Glasbrenner B., Riepl R. L., Malfertheiner P., Büchler M. W. Maldigestion after total gastrectomy is associated with pancreatic insufficiency. Am J Gastroenterol. 1996 Feb;91(2):341–347. [PubMed] [Google Scholar]
  15. Goodlad R. A., Wright N. A. Growth control factors in the gastrointestinal tract. Baillieres Clin Gastroenterol. 1990 Mar;4(1):97–118. doi: 10.1016/0950-3528(90)90041-e. [DOI] [PubMed] [Google Scholar]
  16. Hagmüller E., Kollmar H. B., Günther H. J., Holm E., Trede M. Protein metabolism in human colon carcinomas: in vivo investigations using a modified tracer technique with L-[1-13C]leucine. Cancer Res. 1995 Mar 1;55(5):1160–1167. [PubMed] [Google Scholar]
  17. Harrison L. E., Brennan M. F. The role of total parenteral nutrition in the patient with cancer. Curr Probl Surg. 1995 Oct;32(10):833–917. doi: 10.1016/s0011-3840(05)80013-9. [DOI] [PubMed] [Google Scholar]
  18. Hartl W. H., Demmelmair H., Jauch K. W., Schmidt H. L., Koletzko B., Schildberg F. W. Determination of protein synthesis in human rectal cancer in situ by continuous [1-13C]leucine infusion. Am J Physiol. 1997 May;272(5 Pt 1):E796–E802. doi: 10.1152/ajpendo.1997.272.5.E796. [DOI] [PubMed] [Google Scholar]
  19. Hartl W. H., Miyoshi H., Jahoor F., Klein S., Elahi D., Wolfe R. R. Bradykinin attenuates glucagon-induced leucine oxidation in humans. Am J Physiol. 1990 Aug;259(2 Pt 1):E239–E245. doi: 10.1152/ajpendo.1990.259.2.E239. [DOI] [PubMed] [Google Scholar]
  20. Heppner G. H., Miller B. E. Therapeutic implications of tumor heterogeneity. Semin Oncol. 1989 Apr;16(2):91–105. [PubMed] [Google Scholar]
  21. Heys S. D., Park K. G., Garlick P. J., Eremin O. Nutrition and malignant disease: implications for surgical practice. Br J Surg. 1992 Jul;79(7):614–623. doi: 10.1002/bjs.1800790707. [DOI] [PubMed] [Google Scholar]
  22. Heys S. D., Park K. G., McNurlan M. A., Calder A. G., Buchan V., Blessing K., Eremin O., Garlick P. J. Measurement of tumour protein synthesis in vivo in human colorectal and breast cancer and its variability in separate biopsies from the same tumour. Clin Sci (Lond) 1991 Jun;80(6):587–593. doi: 10.1042/cs0800587. [DOI] [PubMed] [Google Scholar]
  23. Heys S. D., Park K. G., McNurlan M. A., Milne E., Eremin O., Wernerman J., Keenan R. A., Garlick P. J. Stimulation of protein synthesis in human tumours by parenteral nutrition: evidence for modulation of tumour growth. Br J Surg. 1991 Apr;78(4):483–487. doi: 10.1002/bjs.1800780430. [DOI] [PubMed] [Google Scholar]
  24. Hilding A., Brismar K., Thorén M., Hall K. Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993 Nov;77(5):1142–1147. doi: 10.1210/jcem.77.5.7521339. [DOI] [PubMed] [Google Scholar]
  25. Imdahl A., Mantamadiotis T., Eggstein S., Farthmann E. H., Baldwin G. S. Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. J Cancer Res Clin Oncol. 1995;121(11):661–666. doi: 10.1007/BF01218524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Jain R. K. Determinants of tumor blood flow: a review. Cancer Res. 1988 May 15;48(10):2641–2658. [PubMed] [Google Scholar]
  27. Johnson L. R. New aspects of the trophic action of gastrointestinal hormones. Gastroenterology. 1977 Apr;72(4 PT2):788–792. [PubMed] [Google Scholar]
  28. Jordan W. M., Valdivieso M., Frankmann C., Gillespie M., Issell B. F., Bodey G. P., Freireich E. J. Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):197–205. [PubMed] [Google Scholar]
  29. Knapp M. L., al-Sheibani S., Riches P. G., Hanham I. W., Phillips R. H. Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem. 1991 Sep;28(Pt 5):480–486. doi: 10.1177/000456329102800510. [DOI] [PubMed] [Google Scholar]
  30. Kobori O., Vuillot M. T., Martin F. Growth responses of rat stomach cancer cells to gastro-entero-pancreatic hormones. Int J Cancer. 1982 Jul 15;30(1):65–67. doi: 10.1002/ijc.2910300112. [DOI] [PubMed] [Google Scholar]
  31. Lahm H., Suardet L., Laurent P. L., Fischer J. R., Ceyhan A., Givel J. C., Odartchenko N. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer. 1992 Mar;65(3):341–346. doi: 10.1038/bjc.1992.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lehy T., Dubrasquet M., Bonfils S. Effect of somatostatin on normal and gastric-stimulated cell proliferation in the gastric and intestinal mucosae of the rat. Digestion. 1979;19(2):99–109. doi: 10.1159/000198330. [DOI] [PubMed] [Google Scholar]
  33. Lockwood T. D., Minassian I. A., Roux L. Protein turnover and proliferation. Turnover kinetics associated with the elevation of 3T3-cell acid-proteinase activity and cessation of net protein gain. Biochem J. 1982 Aug 15;206(2):239–249. doi: 10.1042/bj2060239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. McNurlan M. A., Clemens M. J. Inhibition of cell proliferation by interferons. Relative contributions of changes in protein synthesis and breakdown to growth control of human lymphoblastoid cells. Biochem J. 1986 Aug 1;237(3):871–876. doi: 10.1042/bj2370871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. McNurlan M. A., Heys S. D., Park K. G., Broom J., Brown D. S., Eremin O., Garlick P. J. Tumour and host tissue responses to branched-chain amino acid supplementation of patients with cancer. Clin Sci (Lond) 1994 Mar;86(3):339–345. doi: 10.1042/cs0860339. [DOI] [PubMed] [Google Scholar]
  36. Moyer M. P., Aust J. B., Dixon P. S., Levine B. A., Sirinek K. R. Glucagon enhances growth of cultured human colorectal cancer cells in vitro. Am J Surg. 1985 Dec;150(6):676–679. doi: 10.1016/0002-9610(85)90406-4. [DOI] [PubMed] [Google Scholar]
  37. Murakami H., Masui H. Hormonal control of human colon carcinoma cell growth in serum-free medium. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3464–3468. doi: 10.1073/pnas.77.6.3464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Nixon D. W., Moffitt S., Lawson D. H., Ansley J., Lynn M. J., Kutner M. H., Heymsfield S. B., Wesley M., Chawla R., Rudman D. Total parenteral nutrition as an adjunct to chemotherapy of metastatic colorectal cancer. Cancer Treat Rep. 1981;65 (Suppl 5):121–128. [PubMed] [Google Scholar]
  39. Okazaki K., Miyazaki M., Onishi S., Ito K. Effects of food intake and various extrinsic hormones on portal blood flow in patients with liver cirrhosis demonstrated by pulsed Doppler with the Octoson. Scand J Gastroenterol. 1986 Nov;21(9):1029–1038. doi: 10.3109/00365528608996416. [DOI] [PubMed] [Google Scholar]
  40. Park K. G., Heys S. D., Blessing K., Kelly P., McNurlan M. A., Eremin O., Garlick P. J. Stimulation of human breast cancers by dietary L-arginine. Clin Sci (Lond) 1992 Apr;82(4):413–417. doi: 10.1042/cs0820413. [DOI] [PubMed] [Google Scholar]
  41. Preedy V. R., Garlick P. J. The effect of glucagon administration on protein synthesis in skeletal muscles, heart and liver in vivo. Biochem J. 1985 Jun 15;228(3):575–581. doi: 10.1042/bj2280575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Rhoads R. E. Protein synthesis, cell growth and oncogenesis. Curr Opin Cell Biol. 1991 Dec;3(6):1019–1024. doi: 10.1016/0955-0674(91)90123-g. [DOI] [PubMed] [Google Scholar]
  43. Sherwin R. S., Bastl C., Finkelstein F. O., Fisher M., Black H., Hendler R., Felig P. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest. 1976 Mar;57(3):722–731. doi: 10.1172/JCI108330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tessari P., Nosadini R., Trevisan R., De Kreutzenberg S. V., Inchiostro S., Duner E., Biolo G., Marescotti M. C., Tiengo A., Crepaldi G. Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism. J Clin Invest. 1986 Jun;77(6):1797–1804. doi: 10.1172/JCI112504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Toffolo G., Foster D. M., Cobelli C. Estimation of protein fractional synthetic rate from tracer data. Am J Physiol. 1993 Jan;264(1 Pt 1):E128–E135. doi: 10.1152/ajpendo.1993.264.1.E128. [DOI] [PubMed] [Google Scholar]
  46. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989 Dec 1;49(23):6449–6465. [PubMed] [Google Scholar]
  47. Watanabe N., Matsuyama T., Namba M., Miyagawa J., Itoh H., Komatsu R., Kono N., Tarui S. Trophic effect of glucagon-(1-21)-peptide on the isolated rat ileal mucosal cells. Biochem Biophys Res Commun. 1988 May 16;152(3):1038–1044. doi: 10.1016/s0006-291x(88)80388-7. [DOI] [PubMed] [Google Scholar]
  48. Watson S. A., Clifford T., Sykes R. E., Robinson E., Steele R. J. Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism. Eur J Cancer. 1995 Nov;31A(12):2086–2092. doi: 10.1016/0959-8049(95)00451-3. [DOI] [PubMed] [Google Scholar]
  49. Wilson M. S., West C. M., Wilson G. D., Roberts S. A., James R. D., Schofield P. F. Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. Br J Cancer. 1993 Sep;68(3):501–506. doi: 10.1038/bjc.1993.376. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES